Could the U.S. Buying More COVID Vaccines Hurt Johnson & Johnson and Novavax?

1 min read

Uncle Sam wants more vaccines. The U.S. government is in discussions with Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) about securing 100 million more doses of each of their COVID-19 vaccines.

In this Motley Fool Live video, recorded on Feb. 1, “The Wrap” host Jason Hall and Motley Fool contributors Keith Speights and Danny Vena discuss what impact these additional vaccine purchases might have on two other companies that could soon win Emergency Use Authorization for their COVID-19 vaccines: Johnson & Johnson (NYSE: JNJ) and Novavax (NASDAQ: NVAX).

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

3 Investments That Are Better Than Bitcoin

Next Story

3 Robinhood Stocks Value Investors Will Love

Latest from Blog